Andrea Frustaci | Neurogenetics | Research Excellence Award

Mr. Andrea Frustaci | Neurogenetics | Research Excellence Award

Mr. Andrea Frustaci | National Institute of Infectious Diseases Lazzaro Spallanzani | Italy

Andrea Frustaci is an Italian cardiologist and Associate Professor of Cardiology at Sapienza University of Rome, working at the Policlinico Umberto I Hospital in Rome. He earned his medical degree with highest honors from the Catholic University of the Sacred Heart and later specialized in cardiology. His academic career has included roles as a university researcher and clinician in cardiovascular medicine, focusing on diagnostic and clinical cardiology. Professor Frustaci has made substantial contributions to cardiovascular research and patient care. His scholarly output includes 248 scientific documents, accumulating 12,475 citations, with an h-index of 51, reflecting significant international impact in cardiology and clinical cardiovascular science.

Citation Metrics (Scopus)

20000
15000
10000
5000
0

Citations
12498

Documents
249

h-index
51

Citations

Documents

h-index

View Scopus Profile
View Orcid Profile

Featured Publications

Severe Aortopathy Caused by Fabry Disease
Annals of Internal Medicine Clinical Cases, 2025

Li-Ru Zhao | Neurogenetics | Best Researcher Award

Prof. Dr. Li-Ru Zhao | Neurogenetics | Best Researcher Award

Dr. LR Zhao is a distinguished neuroscientist and professor at the State University of New York Upstate Medical University, with appointments in the Departments of Neurosurgery and Neuroscience & Physiology. He received his M.D. from Hebei Medical College and completed his Ph.D. at Lund University, focusing on neural stem cells, brain plasticity, and neurobiology. His postdoctoral work at the University of Minnesota explored the role of bone marrow stem cells in brain repair. Dr. Zhao’s research career spans multiple institutions, including Northwestern University and Louisiana State University Health Sciences Center, where he progressed from Research Assistant Professor to Associate Professor. His work primarily investigates mechanisms underlying brain repair and regeneration, with emphasis on traumatic brain injury, enriched environment interventions, and neurodegenerative diseases such as Alzheimer’s and CADASIL. He has successfully secured multiple NIH-funded grants, including R01 and R56 awards, totaling several million dollars, and has mentored numerous medical students through summer and research fellowship programs. Dr. Zhao has published 66 peer-reviewed documents, which have been cited 3,238 times by 2,814 documents, yielding an h-index of 27. His contributions have advanced understanding of hematopoietic growth factors in neurorepair, SCF+G-CSF-mediated recovery in chronic TBI, and the cellular mechanisms regulating neurodegeneration and regeneration, establishing him as a leader in translational neuroscience research.

Profiles: Scopus | Linked In

Featured Publications

  • Author(s). (2024). Research guideline recommendations for research on stem cells, human embryos, and gene editing.

  • Author(s). (2024). Hematopoietic growth factors regulate the entry of monocytes into the adult brain via chemokine receptor CCR5. International Journal of Molecular Sciences.

  • Author(s). (2024). Single-cell RNA sequencing reveals immunomodulatory effects of stem cell factor and granulocyte colony-stimulating factor treatment in the brains of aged APP/PS1 mice. Biomolecules.

  • Author(s). (2023). Stem cell factor and granulocyte colony-stimulating factor promote remyelination in the chronic phase of severe traumatic brain injury. Cells.

  • Author(s). (2021). SCF + G-CSF treatment in the chronic phase of severe TBI enhances axonal sprouting in the spinal cord and synaptic pruning in the hippocampus. Acta Neuropathologica Communications.

Nikolaos Marinakis | Neurogenetics | Best Researcher Award

Dr. Nikolaos Marinakis | Neurogenetics | Best Researcher Award

Dr. Nikolaos Marinakis,  Laboratory of Medical Genetics, NKUA, Greece.

Dr. Nikolaos M. Marinakis is a highly accomplished Molecular Biologist and Geneticist whose career has been devoted to the diagnosis and molecular analysis of rare genetic disorders. With over a decade of laboratory experience and a strong academic background, he has steadily advanced from early bench research in molecular biology to become a Clinical Laboratory Geneticist and genome analyst. His expertise spans whole exome and whole genome sequencing, variant interpretation, CNV and RNA sequencing analysis, and the clinical application of Next Generation Sequencing. Notably, he has contributed to over 1500 molecular diagnoses in patients with rare diseases and has gained international recognition through the ESHG observership at Radboud University Medical Center. Dr. Marinakis exemplifies scientific excellence, clinical impact, and collaborative innovation in human genetics.

Profile

Google Scholar

 

🎓 Early Academic Pursuits

Dr. Nikolaos M. Marinakis embarked on his academic journey with a strong passion for understanding human biology at a molecular level. He earned his Bachelor’s degree in Molecular Biology and Genetics from the Democritus University of Thrace (DUTH), where he was actively involved in bench research. His undergraduate thesis focused on the functional characterization of NAT1 polymorphisms in the primate Macaca mulatta, offering an early glimpse into his interest in gene function and enzyme activity. This formative research cultivated his technical proficiency in cloning, site-directed mutagenesis, protein purification, and enzymatic assays—skills that would later become instrumental in his advanced academic and clinical endeavors.

🧬 Professional Endeavors in Genetics

Dr. Marinakis has spent more than a decade immersed in both research and clinical laboratories, gaining broad and deep expertise in molecular diagnostics. His professional foundation was laid at the Laboratory of Medical Genetics at St. Sophia’s Children Hospital, affiliated with the National and Kapodistrian University of Athens (NKUA). Here, he progressed from an MSc student to a PhD candidate and eventually to a Scientific Research Associate. His doctoral research was centered on the use of Next Generation Sequencing (NGS) technologies for diagnosing rare genetic disorders, and his project involved bioinformatic evaluation and functional validation of genomic variants. As a current genome analyst, he supervises Clinical Whole Exome Sequencing, routinely interpreting variants in over 1,500 complex diagnostic cases encompassing neurodevelopmental, nephrological, cardiovascular, and ophthalmological diseases.

🔍 Research Contributions and Focus

Dr. Marinakis’s primary research lies at the intersection of clinical genomics and bioinformatics. His scientific focus is on the molecular investigation of rare monogenic disorders, variant classification, and the integration of novel genomic technologies such as long-read sequencing into diagnostic pipelines. He has also contributed to the development and clinical implementation of molecular assays for both postnatal and prenatal diagnostics. His research continues to unravel the genetic underpinnings of syndromes with previously unknown etiologies, enriching the understanding of human genomic complexity. Through RNA sequencing and CNV analysis, he bridges the gap between genotype and phenotype in a clinical context.

🏅 Accolades and Recognition

In recognition of his significant contributions to human genetics, Dr. Marinakis was awarded a competitive observership by the European Society of Human Genetics (ESHG). This prestigious award enabled him to join the Genome Diagnostics unit at the Radboud University Medical Center in the Netherlands under the mentorship of Professor Christian Gilissen. There, he expanded his expertise in whole genome sequencing, variant annotation, structural variation, and advanced bioinformatic pipelines. His growing recognition as a Clinical Laboratory Geneticist (ErCLG-certified) further underscores his professional standing in Europe’s genetics community.

🧠 Impact on Clinical Genomics

Dr. Marinakis has made a measurable impact on translational medicine by bringing genomic science to the bedside. Through his analysis and interpretation of complex NGS datasets, he has helped diagnose hundreds of patients with elusive genetic conditions, directly improving clinical outcomes and enabling personalized treatment strategies. His ability to convert raw genomic data into meaningful clinical insights has made him a key figure in the field of diagnostic genetics in Greece and beyond. His meticulous approach to variant interpretation, especially in challenging or ambiguous cases, continues to guide clinicians in the decision-making process.

🌍 Influence and Collaboration

A committed collaborator and lifelong learner, Dr. Marinakis maintains strong academic and clinical ties with global institutions. His experiences at NKUA and Radboud UMC have equipped him with a broad international outlook on genomics and rare disease research. He actively contributes to cross-border initiatives and research consortiums focused on data sharing, standardization of bioinformatics pipelines, and discovery of novel disease mechanisms. His LinkedIn presence and professional engagement reflect his dedication to connecting with the wider genetics and biomedical community.

🔮 Legacy and Future Contributions

Looking ahead, Dr. Marinakis is poised to lead initiatives that integrate AI-driven genomic interpretation and third-generation sequencing into clinical practice. He aspires to contribute to national and European genomics strategies aimed at early diagnosis, carrier screening, and reproductive planning. By mentoring younger scientists and continuing to publish translational research, he is building a legacy rooted in both scientific rigor and compassionate care. With his strong foundation and forward-thinking vision, Dr. Marinakis represents a dynamic force in the future of precision medicine and rare disease diagnostics.

Publication

  • Title: Phenotype‐driven variant filtration strategy in exome sequencing toward a high diagnostic yield and identification of 85 novel variants in 400 patients with rare Mendelian disorders
    Authors: NM Marinakis, M Svingou, D Veltra, K Kekou, C Sofocleous, FN Tilemis, …
    Year: 2021

 

  • Title: Germline CNV detection through whole-exome sequencing (WES) data analysis enhances resolution of rare genetic diseases
    Authors: FN Tilemis, NM Marinakis, D Veltra, M Svingou, K Kekou, A Mitrakos, …
    Year: 2023

 

  • Title: Case report: a novel synonymous ARPC1B gene mutation causes a syndrome of combined immunodeficiency, asthma, and allergy with significant intrafamilial clinical heterogeneity
    Authors: I Papadatou, N Marinakis, E Botsa, M Tzanoudaki, M Kanariou, I Orfanou, …
    Year: 2021

 

  • Title: The clinical and genetic spectrum of autosomal-recessive TOR1A-related disorders
    Authors: A Saffari, T Lau, H Tajsharghi, EG Karimiani, A Kariminejad, S Efthymiou, …
    Year: 2023

 

  • Title: Expanded phenotypic spectrum of neurodevelopmental and neurodegenerative disorder Bryant-Li-Bhoj syndrome with 38 additional individuals
    Authors: DE Layo-Carris, EE Lubin, AK Sangree, KJ Clark, EL Durham, …
    Year: 2024

 

  • Title: De novo variants in RNF213 are associated with a clinical spectrum ranging from Leigh syndrome to early-onset stroke
    Authors: T Brunet, B Zott, V Lieftüchter, D Lenz, A Schmidt, P Peters, R Kopajtich, …
    Year: 2024

 

  • Title: SDH-deficient renal cell carcinoma: A case report associated with a novel germline mutation
    Authors: V Milionis, D Goutas, D Vlachodimitropoulos, AC Lazaris, I Kyriazis, …
    Year: 2021

 

  • Title: Towards a standard benchmark for variant and gene prioritisation algorithms: PhEval-Phenotypic inference Evaluation framework
    Authors: Y Bridges, V de Souza, KG Cortes, M Haendel, NL Harris, DR Korn, …
    Year: 2024

 

  • Title: Bi-allelic genetic variants in the translational GTPases GTPBP1 and GTPBP2 cause a distinct identical neurodevelopmental syndrome
    Authors: V Salpietro, R Maroofian, MS Zaki, J Wangen, A Ciolfi, S Barresi, …
    Year: 2024

 

  • Title: Combined exome analysis and exome depth assessment achieve a high diagnostic yield in an epilepsy case series, revealing significant genomic heterogeneity and novel mechanisms
    Authors: D Veltra, FN Tilemis, NM Marinakis, M Svingou, A Mitrakos, K Kosma, …
    Year: 2023

 

✅ Conclusion

Dr. Nikolaos M. Marinakis stands out as a distinguished researcher in the field of medical genetics and genomics. His work bridges cutting-edge molecular research with clinical diagnostics, making a direct impact on patient care and the understanding of rare diseases. His technical expertise, international collaborations, and growing leadership in genomic diagnostics reflect both his current achievements and his potential for future contributions to precision medicine. He is a strong candidate for recognition in any academic or professional forum honoring excellence in translational genomics and biomedical research.

Shilin Luo | Neurogenetics and Molecular Neuroscience | Best Researcher Award

Prof. Shilin Luo | Neurogenetics and Molecular Neuroscience | Best Researcher Award

Prof. Shilin Luo, Xiangya Hospital, Central South University, China.

Dr. Shilin Luo is a leading expert in neuropharmacology and medicinal chemistry, with a strong academic background in traditional Chinese medicine and modern pharmacology. His research focuses on the pathogenesis of neurodegenerative diseases and the development of innovative drug therapies. Through his work at Xiangya Hospital, Central South University, and previous research at Emory University, he has made significant contributions to understanding neurological disorders. His studies on animal models and risk genes have paved the way for novel treatment strategies, earning him international recognition.

Profile

Scopus

Orcid

 

🎓 Early Academic Pursuits

Dr. Shilin Luo’s journey into the world of medical science began with a deep-rooted passion for understanding the complexities of neurological diseases. He earned his Bachelor’s degree in Chinese Materia Medica from Shenyang Pharmaceutical University, where he developed a strong foundation in traditional Chinese medicine and pharmacology. With an insatiable thirst for knowledge, he further pursued a Ph.D. in Medicinal Chemistry at China Pharmaceutical University, specializing in the research of active ingredients in natural products. Under the mentorship of Prof. Wencai Ye, a distinguished scholar, Dr. Luo honed his expertise in medicinal chemistry, paving the way for groundbreaking discoveries in neuropharmacology.

👨‍🎓 Professional Endeavors

To deepen his expertise, Dr. Luo embarked on postdoctoral research at Emory University’s School of Medicine in the Department of Pathology and Laboratory Medicine. Working under the esteemed Prof. Keqiang Ye, he focused on neurobiology and neuropharmacology, contributing significantly to the understanding of neurodegenerative diseases. His research provided novel insights into the molecular mechanisms underlying neurological disorders, positioning him as a leading figure in the field. He later took on a pivotal role as a professor in the Department of Neurology at Xiangya Hospital, Central South University, where he continues to mentor young scientists and advance medical research.

🧪 Contributions and Research Focus

Dr. Luo’s research is primarily dedicated to uncovering the pathogenesis of neurodegenerative diseases and developing therapeutic interventions. His work in animal models of pathogenic and risk genes for neurological disorders has been instrumental in identifying potential drug targets. By integrating traditional Chinese medicine with modern pharmacology, he has contributed to the development of innovative neuroprotective agents. His studies on the molecular mechanisms of neuronal degeneration have led to promising advancements in combating conditions such as Alzheimer’s and Parkinson’s disease.

🏆 Accolades and Recognition

Throughout his career, Dr. Luo has been widely recognized for his groundbreaking contributions to neuropharmacology. His research has been published in high-impact scientific journals, earning him international acclaim. His dedication to scientific excellence has garnered prestigious awards, and he is frequently invited to deliver keynote lectures at global conferences. His work continues to inspire fellow researchers, solidifying his reputation as a distinguished scientist in neurological drug development.

🏰 Impact and Influence

Dr. Luo’s impact extends beyond the laboratory, as he actively contributes to the medical community through mentorship and collaboration. His efforts in integrating traditional Chinese medicinal principles with cutting-edge pharmacological approaches have opened new avenues for drug discovery. His research findings have not only influenced academic discourse but have also laid the groundwork for potential clinical applications, bringing hope to patients suffering from neurodegenerative diseases.

⚛️ Legacy and Future Contributions

As a visionary scientist, Dr. Luo continues to push the boundaries of neurological research. His commitment to translational medicine aims to bridge the gap between laboratory discoveries and clinical applications. By fostering interdisciplinary collaborations and mentoring the next generation of researchers, he is shaping the future of neuropharmacology.

 

Publication

  • Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity
    Authors: Yujie Zhang, Jie Chen, Yanru Li, Bin Jiao, Shilin Luo
    Year: 2025

 

  • The role of the probiotic Akkermansia muciniphila in brain functions: insights underpinning therapeutic potential
    Authors: Ruiling Xu, Yuxuan Zhang, Shurui Chen, Yaohui Zeng, Xuan Fu, Ti Chen, Shilin Luo, Xiaojie Zhang
    Year: 2023

 

  • Nonviral delivery systems for antisense oligonucleotide therapeutics
    Authors: Si Huang, Xin-Yan Hao, Yong-Jiang Li, Jun‑Yong Wu, Da-Xiong Xiang, Shilin Luo
    Year: 2022

 

  • The Microglial membrane receptor TREM2 mediates exosome secretion to promote phagocytosis of amyloid‐β by microglia
    Authors: Si Huang, Xiaoli Liao, Junyong Wu, Xiaojie Zhang, Yamin Li, Daxiong Xiang, Shilin Luo
    Year: 2022

 

  • Correction: Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine
    Authors: Not explicitly listed
    Year: 2021

 

  • Polygonatum sibiricum Polysaccharides Protect against MPP‐Induced Neurotoxicity via the Akt/mTOR and Nrf2 Pathways
    Authors: Si Huang, Haiyan Yuan, Wenqun Li, Xinyi Liu, Xiaojie Zhang, Daxiong Xiang, Shilin Luo, Guodong Zhang
    Year: 2021

 

  • Bushen-Tiansui Formula Improves Cognitive Functions in an Aβ1–42 Fibril-Infused Rat Model of Alzheimer’s Disease
    Authors: Chenxia Sheng, Panpan Xu, Xinyi Liu, Weijun Peng, Daxiong Xiang, Shilin Luo
    Year: 2020

 

  • Osteogenesis activity of isocoumarin a through the activation of the PI3K-Akt/Erk cascade-activated BMP/RUNX2 signaling pathway
    Authors: Not explicitly listed
    Year: 2019

 

  • Akt Phosphorylates NQO1 and Triggers its Degradation, Abolishing Its Antioxidative Activities in Parkinson’s Disease
    Authors: Shilin Luo, Seong Su Kang, Zhi-Hao Wang, Xia Liu, Julia X Day, Zhiping Wu, Junmin Peng, Daxiong Xiang, Wolfdieter Springer, Keqiang Ye
    Year: 2019

 

  • Puerarin-loaded PEG-PE micelles with enhanced anti-apoptotic effect and better pharmacokinetic profile
    Authors: Not explicitly listed
    Year: 2018

 

Conclusion

Dr. Luo’s unwavering dedication to neurological research continues to shape the future of neuropharmacology. His innovative approach, combining traditional medicinal insights with modern scientific advancements, has the potential to revolutionize drug development for neurodegenerative diseases. As a mentor, researcher, and pioneer in his field, his contributions will leave a lasting impact on both academia and clinical medicine, offering hope for more effective treatments in the years to come.